Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Normalization vs Partial Correction of Hemoglobin with Epoetin Alfa in Early Hemodialysis
NCT00261521Phase 3Completed
- Sponsor
- Johnson & Johnson
- Start
- Feb 2000
- Modality
- Biologic, rProtein (Recombinant Protein)
01
Overview
Phase 3, randomised, double-blind trial of epoetin alfa in anemia (2 arms), sponsored by Johnson & Johnson. Primary endpoint: Left Ventricular Volume Index at Week 96. Started Feb 2000; status: completed.
02
Drugs
epoetin alfa
03
Conditions
anemia
Beyond the preview
Go deeper on NCT00261521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00261521.